UBS Global Biopharma Conference 2026
Logotype for United Therapeutics Corporation

United Therapeutics (UTHR) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for United Therapeutics Corporation

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

Commercial performance and TYVASO momentum

  • Q3 total revenue was $833M; TYVASO franchise revenue reached a record $504M.

  • TYVASO growth reflected strong referrals and starts, effective messaging, and deeper physician engagement; the expanded sales force is expected to contribute more in Q4 and 2027.

  • October referrals across the commercial portfolio exceeded 1,000, a record for one month, indicating continued momentum.

  • PH-ILD remains under-penetrated and a major growth driver; PAH is also growing, though more modestly.

  • Settlement guardrails and the expanded sales force are expected to support TYVASO uptake among new PH-ILD patients over time; payer coverage changes may vary.

IPF and PPF opportunities

  • FDA accepted the sNDA for nebulized TYVASO in IPF; the stated PDUFA date is April 26, and preparations include nebulizers and starter kits for at least 10,000 patients.

  • TETON-1 and TETON-2 results were characterized as highly positive; management expects substantial, rapid uptake, while noting real-world discontinuation may differ from trial experience.

  • TETON PPF trial results are expected to be unblinded in Q3 and Q4 2027.

Pipeline and regulatory milestones

  • Ralinepag NDA for PAH was accepted, with a PDUFA date at the end of June 2027; management expects a once-daily oral prostacyclin to have significant opportunity in PAH.

  • SMI filing timing shifted from end-2026 to 2027 after an FDA meeting identified additional CMC and PK work; no patient-outcome data are expected to be needed.

  • Sinopharm is working with the FDA to address inspection findings; the existing ralinepag timeline remains possible, while alternative manufacturers are being evaluated as a contingency.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from United Therapeutics